Ghent University Hospital is one of the largest hospitals in Belgium. It is closely linked to Ghent University, the university's rector also being the hospital's president. Both the university and the hospital are autonomous entities of the Flemish Government.

During the past decade, UZ Gent conducted 745 clinical trials. In the 10-year time frame, 745 clinical trials started and 243 clinical trials were completed, i.e. on average, 32.6% percent of trials that started reached the finish line to date. In the past 5 years, 377 clinical trials started and 171 clinical trials were completed. i.e. 45.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UZ Gent" #1 sponsor was "University Hospital, Ghent" with 169 trials, followed by "Hoffmann-La Roche" with 61 trials sponsored, "University Ghent" with 36 trials sponsored, "Janssen Research & Development, LLC" with 35 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 35 trials sponsored. Other sponsors include 756 different institutions and companies that sponsored additional 343 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UZ Gent" #1 collaborator was "University Ghent" with 33 trials as a collaborator, "University Hospital, Ghent" with 32 trials as a collaborator, "Universitair Ziekenhuis Brussel" with 12 trials as a collaborator, "University Hospital, Antwerp" with 12 trials as a collaborator and "Merck Sharp & Dohme LLC" with 10 trials as a collaborator. Other collaborators include 609 different institutions and companies that were collaborators in the rest 412 trials.

According to Clinical.Site data, the most researched conditions in "UZ Gent" are "Multiple Myeloma" (26 trials), "Prostate Cancer" (25 trials), "Ulcerative Colitis" (22 trials), "Crohn Disease" (19 trials) and "Crohn's Disease" (18 trials). Many other conditions were trialed in "UZ Gent" in a lesser frequency.

Most popular intervention types in "UZ Gent" are "Drug" (693 trials), "Other" (144 trials), "Device" (114 trials), "Biological" (90 trials) and "Procedure" (90 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (183 trials), "Rituximab" (17 trials), "Cyclophosphamide" (16 trials), "IVA" (14 trials) and "Atezolizumab" (13 trials). Other intervention names were less common.

The vast majority of trials in "UZ Gent" are 949 trials for "All" genders, 85 trials for "Female" genders and 62 trials for "Male" genders.

Currently, there are 397 active trials in "UZ Gent". 7 are not yet recruiting, 243 are recruiting, 143 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 542 completed trials in UZ Gent, 3 suspended trials, and 95 terminated clinical trials to date.

Out of the total trials that were conducted in UZ Gent, 104 "Phase 1" clinical trials were conducted, 268 "Phase 2" clinical trials and 388 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 71 trials, and there were also 179 trials that are defined as “Not Applicable".

UZ Gent has several departments that took part in Clinical trials: "UZ Gent-Reuma" - 6 trials, "UZ Gent Hematology" - 5 trials, "UZ Gent Gastroenterology" - 5 trials, "UZ Gent Medische Oncologie" - 4 trials, "Diensthoofd wondkliniek, UZ Gent" - 2 trials, "Endocrinology, UZ Ghent Hospital" - 2 trials, "University Hospital Gent Pediatrische hemato-oncologie" - 2 trials